Yarrow Bioscience, Inc.
Close on Oct 19, 2026
- Market cap
- $17.14M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 28, 2026 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 30, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $200.00K | $-0.20 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 6, 2025 | Before market open | $84.00K | $-0.28 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $100.00K | $-0.29 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | $200.00K | $-0.22 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | $100.00K | $-0.15 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | Before market open | $76.00K | $-0.20 | $-0.18 |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | Before market open | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 11, 2023 | After market close | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 9, 2023 | After market close | – | – | – |
Press releases
Announcements Yarrow Bioscience filed with the SEC
1 Bringing life into balance Yarrow Bioscience Overview September 2026
Other events · EX-99.1 to Form 8-K
PART I, ITEM 1. BUSINESS
Other events · EX-99.2 to Form 8-K
In connection with the closing of the Merger (as
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K/A
connection with the closing of the Merger (as defined below in Note 1), Yarrow Bioscience, Inc. changed its name to Yarrow Bioscience
Results of operations · Regulation FD disclosure · EX-99.4 to Form 8-K/A
YARROW MANAGEMENT’S DISCUSSION and ANALYSIS
Results of operations · Regulation FD disclosure · EX-99.5 to Form 8-K/A
Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class
Material agreement · Acquisition or disposition completed · Results of operations · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
1 Bringing life into balance July 2026
Material agreement · Acquisition or disposition completed · Results of operations · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
VYNE Therapeutics Announces 1-for-50 Reverse
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
1 Bringing life into balance July 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
VYNE Therapeutics Declares Special Cash Dividend
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
1 Bringing life into balance Yarrow Bioscience Overview May 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics and Yarrow Bioscience Announce Merger Agreement
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Dave Domzalski, CEO of VYNE Therapeutics
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
VYNE Therapeutics Reports 2025 Second Quarter
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo
Results of operations · Other events · EX-99.1 to Form 8-K
Repibresib (VYN201) Phase 2b Topline Results
Results of operations · Other events · EX-99.2 to Form 8-K
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Forward Looking Statements and Important Notes
Other events · EX-99.1 to Form 8-K
Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor
Other events · EX-99.1 to Form 8-K
VYN202 P1a SAD/MAD Data December 2024
Other events · EX-99.2 to Form 8-K
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
VYNE Therapeutics Announces Positive Phase 1a SAD Data
Other events · EX-99.1 to Form 8-K
VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
VYNE Reports 2023 Fourth Quarter and Year-End
Results of operations · EX-99.1 to Form 8-K
Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
VYNE Therapeutics Reports Third Quarter 2023
Results of operations · EX-99.1 to Form 8-K
VYNE Therapeutics Announces Private Placement
Material agreement · Agreement terminated · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
VYNE Therapeutics Announces Positive Data from
Material agreement · Agreement terminated · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
VYNE Therapeutics Reports Positive Results from
Material agreement · Agreement terminated · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
VYNE Therapeutics Regains Compliance with Nasdaq
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
VYNE Therapeutics Reports Third Quarter 2022
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
InhiBET BET Inhibitor Platform Bromodomain & Extra - Terminal Domain (BET) Inhibition for Immunology and Inflammatory Diseases 5
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
VYNE Therapeutics Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K